Can we afford to eliminate restenosis? Can we afford not to? by Greenberg, Dan et al.
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Over the past decade, coronary stenting has emerged as the dominant form of percutaneous
coronary revascularization. However, bare metal stents remain limited by a high incidence of
restenosis, leading to frequent repeat revascularization procedures and substantial economic
burden. Antiproliferative drug-eluting stents (DES) have recently demonstrated dramatic
reductions in rates of restenosis, compared with conventional stenting, but important
concerns about their costs have been raised. In this article, we summarize current evidence on
the economic impact of restenosis and explore the potential benefits and economic outcomes
of DES. In addition to examining the long-term costs of this promising technology, we
consider the potential cost-effectiveness of DES from a health care system perspective and the
impact of specific patient, lesion, and provider characteristics on these parameters. (J Am
Coll Cardiol 2004;43:513–8) © 2004 by the American College of Cardiology Foundationb
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pince it was first introduced in 1977, percutaneous coronary
ntervention (PCI) has revolutionized the treatment of
atients with coronary artery disease (CAD) (1). Despite
ngoing technologic advances resulting in improved safety
nd predictability (2), the “Achilles heel” of PCI has
emained restenosis. Although coronary stenting has re-
uced the rates of angiographic and clinical restenosis,
ompared with conventional balloon angioplasty (3–5),
n-stent restenosis continues to occur in 15% to 20% of
deal coronary lesions and in as many as 30% to 60% of
atients with more challenging characteristics (e.g., small
essels, diffuse disease, bifurcation lesions). When it occurs,
n-stent restenosis may be difficult to treat and has a high
ecurrence rate (6). Thus, there is a considerable impetus for
he development of new therapies to reduce the rate of
estenosis after coronary stenting.
See page 507
Drug-eluting stents (DES) represent one of the most
nnovative developments in interventional cardiology today.
tudies involving several different stent platforms and anti-
roliferative drug coatings have recently demonstrated dra-
atic reductions in restenosis rates, compared with conven-
ional bare metal stents (BMS) (7–11). Although the
linical benefits of DES are increasingly evident, important
oncerns about their costs have been raised (12). The aims
f this report are to summarize the current evidence on the
conomic impact of restenosis and to explore the potential
From the *Harvard Clinical Research Institute, Boston, Massachusetts; †Division
f Cardiology, Beth Israel–Deaconess Medical Center, Boston, Massachusetts; and
he ‡Clinical Trials and Evaluation Unit, Royal Brompton Hospital, London, United
ingdom. Dr. Cohen has received grant support from manufacturers of both
rug-eluting and bare metal stents, including Cordis Corp. (Miami Lakes, Florida),
oston Scientific (Natick, Massachusetts), Guidant (Santa Clara, California), and
edtronic (Minneapolis, Minnesota).
Manuscript received August 4, 2003; revised manuscript received November 6,S003, accepted November 13, 2003.enefits and economic outcomes of using DES in patients
ndergoing PCI.
linical and economic burden of restenosis. Since the
ajor proven benefit of DES is to reduce coronary reste-
osis, it is important to appreciate the clinical and economic
utcomes associated with restenosis to better understand the
xpected benefits of its prevention.
ESTENOSIS AND MORTALITY. To date, no studies have
emonstrated a convincing link between restenosis and
ither short- or long-term mortality. Unlike patients with de
ovo lesions, where plaque rupture and local thrombus
ormation may lead to acute myocardial infarction and
eath, clinically significant coronary restenosis is the result
f progressive lumen renarrowing due to neointimal hyper-
lasia and vascular remodeling and generally presents as a
radual recurrence of anginal symptoms that only rarely
esults in myocardial infarction.
Several lines of clinical evidence confirm the generally
enign prognosis of coronary restenosis. Although rates of
epeat revascularization after percutaneous transluminal cor-
nary angioplasty are 5- to 10-fold higher than after
oronary artery bypass graft surgery (CABG), most ran-
omized trials have failed to demonstrate differences in
ong-term survival between these alternative forms of revas-
ularization (13,14). Moreover, in a study of more than
,300 patients, Weintraub et al. (15) failed to identify any
ifferences in six-year mortality between patients with and
hose without restenosis. Taken together, these findings
uggest that even dramatic reductions in restenosis by DES
re unlikely to substantially improve survival for patients
ndergoing PCI.
ESTENOSIS AND QUALITY OF LIFE (QOL). In contrast, re-
tenosis clearly has an adverse impact on QOL. In the
PUS-1 trial, patients without restenosis had less frequent
ngina, less physical limitations, and improved QOL, com-
ared with patients with restenosis (16). Moreover, in the
tent-PAMI trial, Rinfret et al. (17) found that compared
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Can We Afford Drug-Eluting Stents? February 18, 2004:513–8ith conventional balloon angioplasty, initial stenting was
ssociated with significantly better QOL at six-month
ollow-up—differences that were primarily explained by the
ower rates of angiographic and clinical restenosis associated
ith stenting. Although no studies to date have directly
ompared QOL between patients receiving DES and con-
entional stents, it is nonetheless reasonable to assume that
he lower rates of clinical restenosis and repeat interventions
n patients treated with DES would have a positive impact
n their QOL.
CONOMIC BURDEN OF RESTENOSIS. To fully understand
he economic burden of restenosis to the health care system,
ne must consider both the frequency of clinically important
estenosis and the additional health care costs associated with
ts diagnosis and treatment. Most data regarding the impact
f restenosis on long-term costs after PCI are based on
linical trials (18–21) or single-center series (22). Although
hese studies have limited generalizability to the overall PCI
opulation, they nonetheless provide several important in-
ights. For example, in the ESPRIT trial, the mean cost for
hospital admission to treat clinical restenosis was $11,913
vs. $10,430 for an index hospitalization). On a population
asis, treatment of restenosis added an average of $1,675 to
ach patient’s cost of care during the first year after stenting
21). This value may be considered the direct “economic
urden” of restenosis in the ESPRIT trial population.
imilar findings were noted in the Stent-PAMI trial of
atients with acute myocardial infarction (19). Higher costs
or each episode of clinical restenosis have been noted in
everal distinct populations, including patients undergoing
CI for in-stent restenosis (23) and patients undergoing
ultivessel PCI (22). These diverse studies demonstrate
hat just as there is no single “restenosis rate” for all patients
ho undergo PCI, there is no single cost or economic
urden of restenosis; these values vary substantially accord-
ng to the specific patient population under consideration.
We have recently performed a study to determine the cost
nd economic burden of restenosis within the U.S. Medi-
are program (24). In this population, we found that the
ncidence of repeat revascularization between one month
nd one year after initial PCI was 16.3%. When one
onsiders that 10% to 15% of repeat revascularization
rocedures during the first year after PCI are related to
Abbreviations and Acronyms
BMS  bare metal stent(s)
CABG coronary artery bypass graft surgery
CAD  coronary artery disease
DES  drug-eluting stent(s)
DRG  diagnosis-related group
PCI  percutaneous coronary intervention
QALY  quality-adjusted life-year
QOL  quality of life
TVR  target vessel revascularizationreatment of other coronary lesions and not restenosis, these eopulation-based data indicate that the “real-world” clinical
estenosis rate in contemporary PCI patients is 14%. In
his study, we found that the direct one-year cost of clinical
estenosis was $19,000 per episode, and the economic
urden of restenosis was thus$2,500 per PCI patient (i.e.,
6%  0.85  $19,000).
These data provide an important set of insights into the
xpected economic impact of DES within the U.S. health
are system. The current list price for one CYPHER
Cordis Corp., Miami Lakes, Florida) sirolimus-eluting
tent in the U.S. is $3,195. With volume discounts to many
enters, the average acquisition cost (as of November 1,
003) is currently $2,700/stent. Thus, when compared
ith an average cost of $700 per BMS, the incremental cost
f each DES is currently about $2,000. To estimate the
mpact of DES on initial treatment costs, one must also
onsider that many stent procedures require more than one
tent. In some cases, this is due to limitations in stent
ength, requiring implantation of multiple stents to cover a
oronary lesion that is longer than the longest stent avail-
ble. In addition, additional stents may be required to treat
omplications of the initial stent implantation (e.g., edge
issection), diseased side branches, or multivessel CAD.
Although national estimates are not readily available, data
rom several contemporary studies indicate that mean stent
se is 1.4 per procedure (20,25). Thus, conversion of the
urrent PCI population from BMS to DES would be
xpected to increase initial hospital costs by an average of
$2,800/patient treated (i.e., 1.4 stents/procedure 
2,000/stent). This value may represent an underestimate of
he true increase in procedural costs associated with conver-
ion to DES, however. Preliminary data suggest that the
ong-term results of DES may be optimized by implanting
omewhat longer stents than is common with current BMS
echnology (9). If this approach results in an increase in
ean stent utilization per procedure, the net increase in
nitial hospital cost might be even $2,800 per procedure.
Based on these projections, it is evident that uniform
onversion of all current BMS procedures to DES will not
esult in net cost savings to the U.S. health care system.
ven if DES were to eliminate coronary restenosis, the
esulting savings ($2,500/patient treated) would not fully
ffset the higher cost of the stents themselves. Given current
evels of efficacy (75% to 80% relative risk reductions),
owever, more modest cost offsets are likely. Thus, the
ecision to adopt DES into standard clinical practice must
onsider whether the benefits of this technology are “worth
he costs.”
ptimizing the use of DES: insights from cost-
ffectiveness analysis. No single criterion can define the
ptimal patient population and utilization rate for DES. At
minimum, patient selection for DES implantation should
e based on careful assessment of therapeutic efficacy, short-
nd long-term side effects, generalizability of the available
linical trials to additional patient subsets, and cost-
ffectiveness. Currently, the only DES approved for clinical
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February 18, 2004:513–8 Can We Afford Drug-Eluting Stents?se in the U.S. is the CYPHER stent. Based on data from
andomized, controlled trials, the Food and Drug Admin-
stration (FDA) has approved the use of this stent in
atients with symptomatic ischemic heart disease due to
iscrete, de novo lesions 30-mm long in native coronary
rteries with a reference vessel diameter of 2.5 to 3.5 mm.
ong-term follow-up, as well as experience with more
omplex lesions and in-stent restenosis, is now accumulat-
ng in ongoing clinical trials and registries and may expand
hese indications considerably in the near future.
From the patient’s perspective, DES would ideally be
sed to treat all lesions for which there was even a small
xpectation of benefit. However, in the short term, it is
ikely that the high cost associated with this technology may
orce hospitals and interventional cardiologists to limit
tilization of DES to those high-risk patients who would be
xpected to derive the greatest absolute clinical benefit (12).
ost-effectiveness analysis provides an important frame-
ork that can be used to support the development of such
uidelines.
To assess the economic value of any new medical tech-
ology, it is essential that the new technology be compared
ith the current standard of care (26). Cost-effectiveness
nalysis is a method of comparing the expected benefits of a
edical technology with the net cost of the technology (27).
his relationship is expressed in terms of an incremental
ost-effectiveness ratio, which is calculated by dividing the
et cost of the treatment being evaluated (relative to
tandard of care) by its net benefits (also compared with
tandard of care):
Incremental cost-effectiveness ratio

CostNew CostStandard
EffectivenessNew EffectivenessStandard
In general, costs are measured in monetary terms,
hereas any valued clinical outcome may be used to measure
ealth benefits. Although any clinically relevant outcome
easure can be used, the standard approach is to assess
ong-term health outcomes in terms of quality-adjusted
ife-years (QALY). The QALY concept uses years of life in
erfect health as a common metric to value both life
xpectancy and QOL. One can calculate QALY by weight-
ng each time interval in a given state of health by its
utility”—a value between 0 and 1 that reflects the individ-
al’s preference for that health state relative to perfect health
utility  1) and death (utility  0) (27).
Once a cost-effectiveness ratio is calculated, it is typically
ompared with cost-effectiveness ratios for other therapies
n a “league table.” The threshold for determining whether
therapy is economically attractive varies with the available
ealth care budget. In the U.S., for example, cost-
ffectiveness ratios $50,000 per QALY gained are viewed
s favorable, and cost-effectiveness ratios between $50,000
nd $100,000 per QALY gained are frequently considered
o be in a “gray zone.” In contrast, a cost-effectiveness ratio w$100,000 per QALY saved is viewed as economically
nattractive in virtually all health care systems (including
he U.S.) (28).
Although the use of QALY as an outcome measure in
ost-effectiveness analysis is widely accepted, several prag-
atic issues limit the attractiveness of this end point for
aluing treatments whose principal benefit is preventing
estenosis after PCI. Because there is no evidence that
estenosis affects survival, one would not expect treatments
hose sole benefit is a reduction in restenosis (such as DES)
o improve population-level life expectancy. Although it is
ell recognized that restenosis is associated with reduced
OL (4,16,17), empiric data as to the overall impact of
estenosis on quality-adjusted life expectancy are limited.
Given these limitations, several recent studies have used a
isease-specific cost-effectiveness ratio: cost per repeat re-
ascularization avoided (5,19,23). The advantages of this
nd point are that it is simple to measure, can be easily
ntegrated into standard data collection for clinical trials or
egistries, and is readily interpreted by both clinicians and
atients. The primary limitation of this end point is that it
s specific to the field of coronary revascularization and
annot be compared with cost-effectiveness ratios for other
onditions or against cost-effectiveness analyses using dif-
erent outcome measures. Thus, determination of an appro-
riate cost-effectiveness threshold may be challenging.
Within a specific health care system, however, a compar-
son with other established (and reimbursed) technologies
hat can prevent coronary restenosis may serve as a useful
enchmark. For example, within the U.S. health care
ystem, several technologies with cost-effectiveness ratios
$10,000 per repeat revascularization avoided (e.g., brachy-
herapy for in-stent restenosis, elective coronary stenting vs.
alloon angioplasty) have been widely adopted and are
urrently reimbursed by most third-party payers (5,19).
hese observations suggest that therapies with cost-
ffectiveness ratios $10,000 per repeat revascularization
voided may be considered reasonably attractive within the
.S. health care system.
OST EFFECTIVENESS IN CLINICAL TRIALS. To date, pro-
pective economic analyses have been conducted alongside
wo randomized clinical trials comparing DES with BMS.
he first such study was performed in conjunction with the
AVEL trial (18). The economic analysis was based on
esource utilization from the trial, with unit costs from the
etherlands (in euros), and assumed a cost of 2,000 euros
or each sirolimus-eluting stent. In RAVEL, initial proce-
ural costs were 1,284 euros higher for patients treated with
ES, but reductions in follow-up costs offset most of the
dditional expenses. As a result, at 12-month follow-up, the
irolimus-eluting stent was associated with an additional
ost of only 166 euros per patient.
More recently, we have reported preliminary results from
prospective economic evaluation performed in conjunction
ith the U.S. SIRIUS trial (20). For this study, costs were
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Can We Afford Drug-Eluting Stents? February 18, 2004:513–8ssessed from a U.S. health care system perspective over a
ne-year time horizon. Based on current national averages,
e assumed that each DES would cost $2,700 and each
MS would cost $700. Initial hospital costs were $2,800
igher with the sirolimus-eluting stent than with the BMS
$11,345 vs. $8,464, p  0.001). However, much of this
ifference in initial costs was offset by lower follow-up costs
$5,468 vs. $8,040, p  0.001), mainly due to a reduced
equirement for repeat revascularization procedures. Thus,
t 12 months, the DES strategy cost an average of $309/
atient more than the BMS strategy, yielding cost-
ffectiveness ratios of $1,650 per repeat revascularization
voided and $27,500 per QALY gained.
It is important to recognize that the results of these
rial-based economic studies cannot necessarily be extrapo-
ated to the conditions of routine clinical practice. For
xample, although both studies incorporated adjustments or
vent adjudication to limit the extent to which protocol-
riven costs affected the economic outcomes, it is difficult to
ully account for the impact of the “oculostenotic reflex” on
igure 1. Relationship between the rate of TVR with bare metal stent
mplantation and the incremental cost-effectiveness of drug-eluting stent
mplantation for patients undergoing single-vessel percutaneous coronary
ntervention. Basic assumptions of the cost-effectiveness model are de-
cribed in the text. The model projects that drug-eluting stent implantation
ill be reasonably cost-effective (i.e., cost-effectiveness ratio $10,000/
epeat revascularization avoided) for patients with an expected bare metal
tent TVR rate 12% and cost-saving for patients with TVR 20%.
Table 1. Predicted Rates of Clinical Restenosi
Lesion Length, Reference Vessel Diameter, an
Vessel
Diameter
(mm)
10 15 20
2.5 18% 21% 24%
3.0 12% 14% 16%
3.5 8% 9% 10%
4.0 5% 6% 7%
2.5 11% 13% 15%
3.0 7% 8% 10%
3.5 5% 5% 6%
4.0 3% 4% 4%*Based on a logistic regression model of 4,227 patients undergoing blinical outcomes in a trial that incorporates routine angio-
raphic follow-up. Moreover, patients enrolled in clinical
rials are highly selected and are often treated in high-
olume medical centers, thus limiting the generalizability of
rial results.
OST-EFFECTIVENESS MODELS. To overcome these limita-
ions, we have developed a decision-analytic model to
valuate the cost effectiveness of DES for patients under-
oing single-vessel PCI (29,30). The model’s perspective is
hat of the U.S. health care system. Data for the model were
erived from a database that currently contains one-year
utcomes on more than 6,000 patients undergoing PCI
ith conventional stent implantation (31). Costs for revas-
ularization procedures, their associated complications, and
reatment of restenosis were based on pooled economic data
rom several multicenter trials of contemporary PCI involv-
ng more than 3,000 patients (29). Key assumptions of the
odel were based, to the extent possible, on empirically
erived data and included an average target vessel revascu-
arization (TVR) rate for BMS of 14% (24,31,32), an 80%
eduction in TVR with DES (7,8), an incremental cost of
2,000 per DES, and mean utilization of 1.3 stents per
ingle-vessel stent procedure (25).
Over a two-year follow-up period, this model projected
hat overall medical care costs with DES would be $900/
atient higher than with BMS, with an incremental cost-
ffectiveness ratio of $7,000 per repeat revascularization
voided. Sensitivity analyses demonstrated that treatment
ith DES would be cost saving for patients with a BMS
VR rate 20% and cost effective (i.e., cost-effectiveness
atio $10,000/repeat revascularization avoided) for pa-
ients with a BMS TVR rate 12% (Fig. 1).
Further insight into the ideal patient population for implan-
ation of DES may be derived from statistical models to predict
estenosis after BMS implantation. Most studies have identi-
ed a smaller reference vessel diameter, a greater lesion length,
nd the presence of diabetes as consistent predictors of both
ngiographic and clinical restenosis after conventional stent
er Bare Metal Stenting as a Function of
abetes*
ion Length (mm)
25 30 35 40
iabetic Patients
28% 33% 38% 45%
18% 21% 25% 29%
12% 14% 16% 19%
8% 9% 10% 12%
-diabetic Patients
18% 21% 24% 28%
11% 13% 15% 18%
7% 9% 10% 12%
5% 6% 6% 7%s Aft
d Di
Les
D
Nonare metal stent implantation and clinical follow-up only (31).
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February 18, 2004:513–8 Can We Afford Drug-Eluting Stents?mplantation (31,33). A predictive model for clinical restenosis
fter stent implantation based on these three predictive factors
s displayed in Table 1 (31). By combining these predicted
estenosis rates with the previously described cost-effectiveness
odel, it is possible to estimate the cost effectiveness of DES
or a variety of specific patient and lesion characteristics. This
pproach demonstrates that compared with conventional
tents, DES would be cost saving for only a modest proportion
f the current PCI population. On the other hand, these
odels also indicate that DES should be economically attractive
i.e., cost-effectiveness ratio $10,000 per repeat revascular-
zation avoided) for virtually all-diabetic patients and for
on-diabetic patients with smaller vessels (reference vessel
iameter 3.0 mm) and longer lesions (lesion length 15
m).
hat is the expected budget impact? As we have out-
ined, when the analysis is restricted to the current U.S. PCI
opulation, universal adoption of DES is unlikely to reduce
et health care costs. In fact, with an expected incremental
wo-year cost of $900 per treated patient, the use of DES
n 80% of the current PCI population would be expected to
ncrease annual U.S. health care costs by almost $500
illion. Nonetheless, it is possible that DES could eventu-
lly result in meaningful long-term cost savings to the
ealth care system. In particular, the use of DES for patients
ho currently undergo CABG (at a cost of $25,000)
ould result in substantial short- and long-term cost savings.
f the need for repeat revascularization after multivessel
ES implantation were comparable to that after bypass
urgery, with similar long-term survival and angina relief,
ost savings of $5,000 to $10,000 per converted patient
ight be achieved. Given these cost savings, it is conceiv-
ble that conversion of 20% to 30% of the current U.S.
ABG volume to DES could result in sufficient savings to
he health care system to offset the higher long-term costs of
ES for the current PCI population. Whether the clinical
esults of multivessel PCI with DES can match these
enchmarks and whether such volume shifts are achievable
iven current practice patterns await future investigation.
Finally, it is important to recognize that the current
conomic impact of DES is likely to be mitigated in the
uture by price reductions due to market competition.
uring the first five years after introduction of BMS in the
.S., prices fell 25%. Comparable price reductions for
ES would render them cost neutral (or cost saving) for the
ast majority of the current PCI population.
lternative perspectives. The preceding discussion has fo-
used on the economic impact of DES from a health care
ystem perspective. When considering the overall economic
mpact of DES, however, it is important to recognize that
lternative perspectives may be more relevant to different
takeholders.
HE HOSPITAL PERSPECTIVE. In a landmark decision, the
enter for Medicare and Medicaid Services established two
ew diagnosis-related groups (DRGs) for PCI to reimburse Dospitals for DES procedures before their FDA approval.
s of August 2003, the average reimbursement for DES
mplantation was $1,800 higher than that for a compara-
le hospitalization involving only BMS implantation. Given
he current price of the CYPHER stent and the expected
tilization of 1.4 (or more) stents per procedure, it is
nlikely that the new reimbursement will fully cover the
ncremental cost to the average U.S. hospital. Although this
eflects a scenario for the “typical” U.S. hospital, it is
mportant to recognize that the incremental reimbursement
s also affected by a variety of hospital characteristics (e.g.,
eographic location, teaching status) and will thus be higher
r lower than the average for most institutions. Thus, the
rofitability of DES procedures for each hospital reflects a
omplex interplay between the DRG payment rate, the
umber of stents used per procedure, and the acquisition
ost of DES. Currently, using DES for lesions that can be
reated with one stent is the only option that will minimize
hospital’s financial loss.
Insufficient third-party reimbursement accounts for only
art of the financial shortfall that hospitals will face with
idespread adoption of DES, however. Given the benefits
f DES in reducing restenosis, hospitals will face further
oss of revenue due to the expected downstream reduction in
he need for repeat revascularization procedures. Finally,
nd most importantly, hospitals will face a loss of revenue
ue to the expected substitution of less remunerative DES
rocedures for CABG—a highly lucrative and profitable
rocedure for many hospitals. At least one study, performed
rom the perspective of a large, tertiary medical center,
rojected annual losses of $3.8 to $6 million during the first
ve years after the introduction of DES (34).
onclusions. The development of DES has been hailed as
true breakthrough in interventional cardiology. Although
he use of DES is unlikely to reduce already low rates of
n-hospital death and myocardial infarction in patients
eceiving PCI, substantial reductions in restenosis and
epeat revascularization should be apparent within the first
to 12 months after their introduction. As a result, the
emand for these devices by both the clinician and patient
s high and, in the short term, has actually exceeded DES
upplies by many accounts.
Currently there is no single answer to the question: “Are
rug-eluting stents cost effective?” The cost effectiveness of
ES depends on the target population and the specific
reatment comparator (e.g., BMS, CABG, or medical
herapy), as well as on the perspective of the analysis.
onetheless, at least for the patient population that cur-
ently undergoes PCI in the U.S., simulation models as well
s prospective analyses from clinical trials suggest that DES
ill be reasonably cost effective for the majority of patients
nd even cost saving for a large subgroup of patients who are
t relatively high risk of clinical restenosis with conventional
CI techniques. In the future, lower incremental costs for
ES should render this technology cost saving for a much
l
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opulation.
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